絞り込み

16525

広告

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.

著者 von Moos R , Body JJ , Rider A , de Courcy J , Bhowmik D , Gatta F , Hechmati G , Qian Y
J Bone Oncol.2018 Jun ; 11():1-9.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (14view , 0users)

Full Text Sources

Miscellaneous

Bone metastases (BMs) are common in patients with breast cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), like zoledronic acid and denosumab, reduce the incidence of SREs and delay progression of bone pain.
PMID: 29892519 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード